Development of a Hybridization LC-MS Methodology for Quantitation of siRNA in Cynomolgus Monkey
Quantitative Bioanalysis of HT-KIT Vivo-Morpholino Using Hybridization LC-MS/MS
Strategies to Improve Assay Sensitivity for Bioanalysis of Therapeutic Oligonucleotides Through Ligand Binding Assays
Altasciences’ Chief Scientific Officer Named a PharmaVoice 100 Honoree
Greater Montréal, Québec, October 9, 2024 — Altasciences is proud to announce that Dr. Beatrice Setnik, PhD, has been honored as a PharmaVoice 100 winner. Dr. Setnik made the list of 100 honorees for her hands-on leadership and nearly 20 years of experience in clinical drug development, with a focus on abuse potential studies. In addition to her role as Chief Scientific Officer (CSO) at Altasciences, she serves as an adjunct professor at the University of Toronto and helps develop educational programs for children in her spare time.
PharmaVoice featured Dr. Setnik in an exclusive interview, highlighting her contributions to the life sciences field, and deeper insights into her visionary leadership and expertise. Selected from nominations by readers and colleagues, each honoree was evaluated by the PharmaVoice team and categorized into 10 distinct groups: Standout Leaders, Cancer Care Visionaries, Cardiometabolic All-Stars, Trailblazers, Biotech Pathfinders, Rare Disease Warriors, Tech and AI Wizards, Clinical Trial Pros, Patient Champions, and Cell and Gene Therapy Pioneers. Each winner represents the transformative impact of the pharmaceutical industry in their own unique way.
"Thank you very much to PharmaVoice for this honor, which would have been impossible without the support of my colleagues, the clients at Altasciences, and of course, my peers and collaborators over the years,” said Dr. Setnik. “To be included in a list of such incredible innovators and trailblazers is extremely humbling."
Dr. Setnik joined Altasciences as Chief Scientific Officer in 2019, working with her team to develop new clinical methods to safely study compounds in early-phase drug development, and adapting clinical methods to establish a safe, comfortable, stimulus-controlled environment for study participants. She has been previously recognized as a “Scientific Trailblazer” by Insights Care and was named one of the 30 Most Influential People in the Pharma Industry by The Medicine Maker in 2024.
“These honorees are inspirations. Their teams look to them for guidance, their patients for support, and their organizations for direction. Each winner represents progress toward a healthier future for everyone that is bolstered by science and technological advancements. We are excited to recognize their contributions through this annual list,” said Meagan Parrish, Lead Editor, PharmaVoice.
Since 2005, the PharmaVoice 100 has become one of the publication’s most anticipated features. From academia and nonprofits to Big Pharma, startups and tech companies, it is the only awards program in the industry that honors individuals from all sectors of life sciences. These honorees, from the clinic to the C-suite, are making meaningful contributions to their fields and striving to improve outcomes for patients around the world.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit altasciences.com.
About PharmaVoice
PharmaVoice is a leading industry publication operated by Industry Dive. Our stories deliver the most important voices and ideas in the life sciences to industry leaders.
About Industry Dive
Industry Dive, an Informa business, is a leading business journalism company. Over 14 million decision-makers across 20+ competitive industries rely on our exclusive insight and analysis delivered through more than 30 publications.
Julie-Ann Cabana
Altasciences
+1 514 601-9763
jcabana@altasciences.com
The 2024 PharmaVoice 100: Dr. Beatrice Setnik, Chief Scientific Officer, Altasciences
Shaping the Future of Medicine: Pharmaceutical Formulation Development
Endpoints News: Clive Meanwell's New Obesity Biotech, Metsera, Unveils Early GLP-1 Data With an Eye on Phase 3 Next Year
Nanomilling―Enhanced Drug Solubility and Bioavailability
ISSUE NO. 41 — Immunomodulation Assessments for Clinical Trials: Sophisticated Bioanalytical Approaches to Support Complex Modalities
Immunomodulatory drugs are at the forefront for the treatment of various types of cancer, infectious diseases, and numerous autoimmune diseases, including rheumatoid arthritis, type I diabetes, lupus, and multiple sclerosis. As the complexity of these therapeutics increases, so must the sophistication of the bioanalytical assays designed to either quantify them or measure their impact on the patient.
In Issue 41 of The Altascientist, we explore common classes of immunomodulators, bioanalytical methods used to quantify them, and their associated biomarkers. Featuring two scenarios that explore the complexities of bioanalysis for immunomodulators, The Altascientist offers practical considerations for ensuring accurate bioanalysis, as well as pharmacokinetic, pharmacodynamic, and safety data in clinical trials.
This issue also covers:
• classes of immunomodulators, including monoclonal antibodies, CAR-T cells, and vaccines;
• immunotherapy trials, focusing on complex study designs and diverse patient populations; and
• bioanalytical methods and assays, including pharmacokinetics and anti-drug antibodies (ADA).
Immunomodulation Assessments for Clinical Trials
Immunomodulators can be broadly defined as immunostimulants and immunosuppressants, with many types of modalities. The growing understanding of the immune system's role in various diseases, along with advancements in drug development, have led to a natural evolution from traditional vaccines, small molecules, and cytokines, to increased targeted biologics and innovative approaches in gene therapy and vaccines.
“Each class of immunomodulator has a defined complexity and mechanism of action. Thus, the appropriate bioanalytical program will need to be carefully designed for the drug type and the intended purpose of the clinical study." –The Altascientist, Issue 41 pg. 2.
This includes careful consideration of pharmacokinetic and pharmacodynamic endpoints, as well as regulatory and bioanalytical requirements.
Particular attention is needed for monoclonal antibodies, CAR-T cells, antibody-drug conjugates (ADCs), and vaccines, as each class requires tailored strategies to support clinical studies and ensure accurate data collection.
Explore all issues of The Altascientist in our Resource Center. And don’t forget to subscribe to “The Altascientist: Audiobooks” on Spotify, Apple Podcasts, or wherever you get your audio content.